{"component": "definition", "props": {"groups": [{"size": 11, "snippet": "or \u201cGDP\u201d - distribution in accordance with the principles and guidelines of good distribution practice as in force from time to time in the Territory, or any part thereof, relating to the warehousing, storage and physical distribution of medicinal products established by the applicable Competent or Regulatory Authority.", "samples": [{"hash": "fhST8n6R3SI", "uri": "/contracts/fhST8n6R3SI#good-distribution-practice", "label": "Asset Purchase and License Agreement", "score": 21.4695415497, "published": true}, {"hash": "7T8csnfaXvJ", "uri": "/contracts/7T8csnfaXvJ#good-distribution-practice", "label": "Asset Purchase and License Agreement", "score": 21.4695415497, "published": true}, {"hash": "fo25FklCqNL", "uri": "/contracts/fo25FklCqNL#good-distribution-practice", "label": "Asset Purchase and License Agreement", "score": 21.3572902679, "published": true}], "snippet_links": [{"key": "in-accordance-with", "type": "clause", "offset": [24, 42]}, {"key": "principles-and-guidelines", "type": "clause", "offset": [47, 72]}, {"key": "in-force", "type": "clause", "offset": [106, 114]}, {"key": "from-time-to-time", "type": "clause", "offset": [115, 132]}, {"key": "in-the-territory", "type": "clause", "offset": [133, 149]}, {"key": "relating-to", "type": "definition", "offset": [172, 183]}, {"key": "distribution-of", "type": "clause", "offset": [222, 237]}, {"key": "medicinal-products", "type": "definition", "offset": [238, 256]}, {"key": "the-applicable", "type": "clause", "offset": [272, 286]}, {"key": "regulatory-authority", "type": "clause", "offset": [300, 320]}], "hash": "7949ac948fb518087c93d42dcb2d05f5", "id": 1}, {"size": 7, "snippet": "or \u201cGDP\u201d means all applicable then-current good distribution practice standards that promote the safety and integrity of the pharmaceutical supply chain, including European Commission Directives 2001/83/EC (to combat counterfeit medicines) and 2003/94/EC (good manufacturing practice in respect of medicinal products for human use and investigational medicinal products for human use), and 2011/62/EU (EU Falsified Medicines Directive) and any implementing acts, delegated acts and guidance thereunder, including the European Commission Guideline 2013/C 343/01 on Good Distribution Practice of medicinal products for human use and the European Commission Guideline 2015/C 95/01 on principles of Good Distribution Practice of active substances for medicinal products for human use, or in any similar set of laws, regulations, rules, or practices that are applicable in countries where development activities are or will be carried out under this Agreement or in parts of the Territory in which Product will be sold, including WHO Guidelines;", "samples": [{"hash": "58Ejg8ITMEk", "uri": "/contracts/58Ejg8ITMEk#good-distribution-practice", "label": "Licensing Agreement", "score": 35.2836418152, "published": true}, {"hash": "h5Fj5g0X1lf", "uri": "/contracts/h5Fj5g0X1lf#good-distribution-practice", "label": "Licensing Agreement", "score": 35.2466430664, "published": true}, {"hash": "2xP8fr3PAKJ", "uri": "/contracts/2xP8fr3PAKJ#good-distribution-practice", "label": "Licensing Agreement", "score": 34.4048881531, "published": true}], "snippet_links": [{"key": "practice-standards", "type": "definition", "offset": [61, 79]}, {"key": "safety-and", "type": "definition", "offset": [97, 107]}, {"key": "integrity-of", "type": "clause", "offset": [108, 120]}, {"key": "pharmaceutical-supply-chain", "type": "definition", "offset": [125, 152]}, {"key": "good-manufacturing-practice", "type": "definition", "offset": [256, 283]}, {"key": "in-respect-of", "type": "definition", "offset": [284, 297]}, {"key": "human-use", "type": "definition", "offset": [321, 330]}, {"key": "investigational-medicinal-products", "type": "clause", "offset": [335, 369]}, {"key": "falsified-medicines", "type": "clause", "offset": [405, 424]}, {"key": "implementing-acts", "type": "definition", "offset": [444, 461]}, {"key": "delegated-acts", "type": "definition", "offset": [463, 477]}, {"key": "the-european-commission", "type": "clause", "offset": [513, 536]}, {"key": "active-substances", "type": "clause", "offset": [725, 742]}, {"key": "development-activities", "type": "clause", "offset": [884, 906]}, {"key": "agreement-or", "type": "definition", "offset": [945, 957]}, {"key": "the-territory", "type": "clause", "offset": [970, 983]}], "hash": "e9808c5ac25953caf22eab01cd6e3c52", "id": 2}, {"size": 4, "snippet": "means the applicable principles and guidelines for good distribution practice of drugs and medicinal products, as such principles and guidelines are amended, implemented and supplemented from time-to-time, including without limitation those set out in Guidelines of 5 November 2013 on Good Distribution Practice of medicinal products for human use, based on Article 84 and Article 85b(3) of Directive 2001/83/EC.", "samples": [{"hash": "3qruouJovwt", "uri": "/contracts/3qruouJovwt#good-distribution-practice", "label": "Exclusive Licence Agreement", "score": 31.3408622742, "published": true}, {"hash": "ydHKckhj0g", "uri": "/contracts/ydHKckhj0g#good-distribution-practice", "label": "Exclusive Licence Agreement (Ascendis Pharma a/S)", "score": 28.2511978149, "published": true}, {"hash": "7zVkE6mbhR3", "uri": "/contracts/7zVkE6mbhR3#good-distribution-practice", "label": "Exclusive Licence Agreement (Ascendis Pharma a/S)", "score": 28.2511978149, "published": true}], "snippet_links": [{"key": "guidelines-for", "type": "clause", "offset": [36, 50]}, {"key": "medicinal-products", "type": "definition", "offset": [91, 109]}, {"key": "including-without-limitation", "type": "clause", "offset": [206, 234]}, {"key": "set-out", "type": "definition", "offset": [241, 248]}, {"key": "november-2013", "type": "clause", "offset": [268, 281]}, {"key": "human-use", "type": "definition", "offset": [338, 347]}, {"key": "based-on", "type": "definition", "offset": [349, 357]}, {"key": "directive-2001-83", "type": "definition", "offset": [391, 408]}], "hash": "0897ed55230d520b67d060eaee43756d", "id": 3}, {"size": 4, "snippet": "or \u201cGDP\u201d shall mean the then-current standards for Distribution activities as set forth by the World Health Organization and Applicable Law, as amended from time to time.", "samples": [{"hash": "aBwlPaF8wNh", "uri": "/contracts/aBwlPaF8wNh#good-distribution-practice", "label": "Transitional Supply Agreement", "score": 31.3408622742, "published": true}, {"hash": "94zow6Ixrjp", "uri": "/contracts/94zow6Ixrjp#good-distribution-practice", "label": "Transitional Supply Agreement (Depomed Inc)", "score": 26.9603004456, "published": true}, {"hash": "eMnFH8titOi", "uri": "/contracts/eMnFH8titOi#good-distribution-practice", "label": "Transitional Supply Agreement (Depomed Inc)", "score": 26.3552360535, "published": true}], "snippet_links": [{"key": "current-standards", "type": "clause", "offset": [29, 46]}, {"key": "distribution-activities", "type": "definition", "offset": [51, 74]}, {"key": "organization-and-applicable-law", "type": "clause", "offset": [108, 139]}, {"key": "as-amended", "type": "definition", "offset": [141, 151]}, {"key": "from-time-to-time", "type": "clause", "offset": [152, 169]}], "hash": "138c900e84d87f2a84cb5618686e5f0d", "id": 4}, {"size": 4, "snippet": "means the EC Guidelines of Good Distribution Practice on Medicinal Products for Human Use (2001/83/EC) or equivalent Laws in the Territory.", "samples": [{"hash": "iqrfQZdqavC", "uri": "/contracts/iqrfQZdqavC#good-distribution-practice", "label": "License and Distribution Agreement (Gw Pharmaceuticals PLC)", "score": 24.2306632996, "published": true}, {"hash": "a2bUZI1LwbJ", "uri": "/contracts/a2bUZI1LwbJ#good-distribution-practice", "label": "License and Distribution Agreement (Gw Pharmaceuticals PLC)", "score": 24.0444908142, "published": true}, {"hash": "6u2X4GRddXy", "uri": "https://ir.gwpharm.com/static-files/cbc3be29-f865-4e1e-9dfe-04dc76568710", "label": "Amendment", "score": 11.967830658, "published": false}], "snippet_links": [{"key": "medicinal-products", "type": "definition", "offset": [57, 75]}, {"key": "human-use", "type": "definition", "offset": [80, 89]}, {"key": "or-equivalent", "type": "definition", "offset": [103, 116]}, {"key": "in-the-territory", "type": "clause", "offset": [122, 138]}], "hash": "adc04fc714623b7d0485d8dc75a6b92e", "id": 5}, {"size": 4, "snippet": "means the guidelines for the proper distribution of medicinal products for human use in the Territory, including in accordance with 21 CFR 210/211 and USP 1079, as each may be amended from time to time.", "samples": [{"hash": "gQZXFNhJJDC", "uri": "/contracts/gQZXFNhJJDC#good-distribution-practice", "label": "Supply and License Agreement (HedgePath Pharmaceuticals, Inc.)", "score": 30.1772766113, "published": true}, {"hash": "lxfg6JSOhOv", "uri": "/contracts/lxfg6JSOhOv#good-distribution-practice", "label": "Supply and License Agreement (HedgePath Pharmaceuticals, Inc.)", "score": 24.6153316498, "published": true}, {"hash": "eaQSIONFooO", "uri": "/contracts/eaQSIONFooO#good-distribution-practice", "label": "Supply and License Agreement (HedgePath Pharmaceuticals, Inc.)", "score": 23.4928131104, "published": true}], "snippet_links": [{"key": "guidelines-for", "type": "clause", "offset": [10, 24]}, {"key": "distribution-of", "type": "clause", "offset": [36, 51]}, {"key": "medicinal-products", "type": "definition", "offset": [52, 70]}, {"key": "human-use", "type": "definition", "offset": [75, 84]}, {"key": "in-the-territory", "type": "clause", "offset": [85, 101]}, {"key": "in-accordance-with", "type": "clause", "offset": [113, 131]}, {"key": "from-time-to-time", "type": "clause", "offset": [184, 201]}], "hash": "69f5811dbf286c03be3beceea3fc5fa0", "id": 6}, {"size": 4, "snippet": "means, to the extent applicable, the then-current Good Distribution Practice Guidelines issued by the European Commission to ensure that the level of quality determined by GMP is maintained throughout the distribution network, as set forth in Commission Guidelines 2013/C 343/01 and any and all related Directives, as may be amended from time to time.", "samples": [{"hash": "77rtJW1Wbe9", "uri": "/contracts/77rtJW1Wbe9#good-distribution-practice", "label": "Supply Agreement (Exelixis, Inc.)", "score": 32.3429145813, "published": true}, {"hash": "krYs2IcYGcs", "uri": "/contracts/krYs2IcYGcs#good-distribution-practice", "label": "Supply Agreement (Exelixis, Inc.)", "score": 27.7460651398, "published": true}, {"hash": "4ftETZcNsKU", "uri": "/contracts/4ftETZcNsKU#good-distribution-practice", "label": "Supply Agreement (Exelixis, Inc.)", "score": 27.3381252289, "published": true}], "snippet_links": [{"key": "to-the-extent", "type": "clause", "offset": [7, 20]}, {"key": "practice-guidelines", "type": "definition", "offset": [68, 87]}, {"key": "issued-by", "type": "definition", "offset": [88, 97]}, {"key": "the-european-commission", "type": "clause", "offset": [98, 121]}, {"key": "to-ensure", "type": "clause", "offset": [122, 131]}, {"key": "distribution-network", "type": "definition", "offset": [205, 225]}, {"key": "from-time-to-time", "type": "clause", "offset": [333, 350]}], "hash": "742278f982f430def01cbb307c99cc6c", "id": 7}, {"size": 4, "snippet": "means that practice of purchasing, storing and shipping a regulated pharmaceutical product and billing to and collecting from customers for a regulated pharmaceutical product in accordance with legal requirements and the standards and customary industry commercial practices.", "samples": [{"hash": "3YK8MmI77rU", "uri": "/contracts/3YK8MmI77rU#good-distribution-practice", "label": "Distribution Agreement", "score": 31.3408622742, "published": true}, {"hash": "13RNJ7L4eml", "uri": "/contracts/13RNJ7L4eml#good-distribution-practice", "label": "Distribution Agreement (UNITED THERAPEUTICS Corp)", "score": 22.1471595764, "published": true}, {"hash": "ix45puVTSq0", "uri": "/contracts/ix45puVTSq0#good-distribution-practice", "label": "Distribution Agreement (UNITED THERAPEUTICS Corp)", "score": 21.1533203125, "published": true}], "snippet_links": [{"key": "pharmaceutical-product", "type": "clause", "offset": [68, 90]}, {"key": "in-accordance-with", "type": "clause", "offset": [175, 193]}, {"key": "legal-requirements", "type": "clause", "offset": [194, 212]}, {"key": "the-standards", "type": "definition", "offset": [217, 230]}, {"key": "commercial-practices", "type": "clause", "offset": [254, 274]}], "hash": "16251101322de2745b04152dd15dfcfb", "id": 8}, {"size": 3, "snippet": "means the guidelines on good distribution practice published by the European Commission in accordance with Article 84 of the 2001 Directive;", "samples": [{"hash": "3eJwoHYy3nj", "uri": "https://www.legislation.gov.uk/uksi/2016/190/data.pdf", "label": "www.legislation.gov.uk", "score": 11.0479125977, "published": false}, {"hash": "aCDiW4kMo94", "uri": "https://d353ahjsg66ro4.cloudfront.net/cy/uksi/2016/190/data.pdf", "label": "d353ahjsg66ro4.cloudfront.net", "score": 10.8165636063, "published": false}, {"hash": "f1BsTqFpCNE", "uri": "https://www.legislation.gov.uk/uksi/2013/532/2013-04-01/data.pdf", "label": "www.legislation.gov.uk", "score": 10.2169742584, "published": false}], "snippet_links": [{"key": "the-guidelines", "type": "clause", "offset": [6, 20]}, {"key": "the-european-commission", "type": "clause", "offset": [64, 87]}, {"key": "in-accordance-with", "type": "clause", "offset": [88, 106]}], "hash": "9698be95f2491fa9d5e968752da60e68", "id": 9}, {"size": 3, "snippet": "means distribution practice as set out in the Guidelines on Good Distribution Practice of Medicinal Products for Human Use in the European Community (94/C 63/03) issued by the European Commission.", "samples": [{"hash": "czeyeEQjHXU", "uri": "/contracts/czeyeEQjHXU#good-distribution-practice", "label": "Logistics Agreement (Cell Therapeutics Inc)", "score": 23.8336753845, "published": true}, {"hash": "cgTwGhvqj5B", "uri": "https://investors.ctibiopharma.com/static-files/e747688c-e53d-4b42-b66a-33e39dbb8b01", "label": "investors.ctibiopharma.com", "score": 9.9637231827, "published": false}, {"hash": "braFlb9Xpjg", "uri": "http://investors.ctibiopharma.com/static-files/e747688c-e53d-4b42-b66a-33e39dbb8b01", "label": "investors.ctibiopharma.com", "score": 9.7980833054, "published": false}], "snippet_links": [{"key": "set-out", "type": "definition", "offset": [31, 38]}, {"key": "the-guidelines", "type": "clause", "offset": [42, 56]}, {"key": "medicinal-products", "type": "definition", "offset": [90, 108]}, {"key": "human-use", "type": "definition", "offset": [113, 122]}, {"key": "european-community", "type": "clause", "offset": [130, 148]}, {"key": "issued-by", "type": "definition", "offset": [162, 171]}, {"key": "the-european-commission", "type": "clause", "offset": [172, 195]}], "hash": "5c44fde0344f5900f15f88e17e5b7a8a", "id": 10}], "next_curs": "CmcSYWoVc35sYXdpbnNpZGVyY29udHJhY3RzckMLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIjZ29vZC1kaXN0cmlidXRpb24tcHJhY3RpY2UjMDAwMDAwMGEMogECZW4YACAA", "definition": {"title": "Good Distribution Practice", "size": 73, "snippet": "or \u201cGDP\u201d - distribution in accordance with the principles and guidelines of good distribution practice as in force from time to time in the Territory, or any part thereof, relating to the warehousing, storage and physical distribution of medicinal products established by the applicable Competent or Regulatory Authority.", "id": "good-distribution-practice", "examples": ["Destruction of stock remaining at CA site is to be performed by CG, in accordance with Good Manufacturing Practice, <strong>Good Distribution Practice</strong>, Good Clinical Practice and in accordance with any National Regulatory requirement.", "Destruction of stock remaining at CA site is to be performed by CG, in accordance of Good Manufacturing Practice, <strong>Good Distribution Practice</strong> and in accordance with any National Regulatory requirement.", "All quality-relevant matters for pharmaceutical contract products, including compliance with the guidelines of Good Manufacturing Practice (GMP) and <strong>Good Distribution Practice</strong> (GDP), shall be regulated in a separate agreement (QAA / Quality Assurance Agreement).", "To specify the roles and responsibilities of the respective parties thereby ensuring compliance to Guidelines of 5 November 2013 on <strong>Good Distribution Practice</strong> of Medicinal Products for Human Use (2013/C 343/01).", "Sponsor is responsible for packing and shipping of Study Drug (IMP) in a proper manner, so that quality and storage conditions are maintained during transport until arrival and receipt at receiver, safety is ensured and that all applicable regulations are met including The Guidelines of 5 November 2013 on <strong>Good Distribution Practice</strong> of medicinal products for human use (GDP) chapter 7 and 9.", "The Buyer must comply with all applicable laws and regulations, including the Guidelines of Good Manufacturing Practice for Medicinal Products and the Guide to <strong>Good Distribution Practice</strong>.", "Sponsor is responsible for packing and shipping of Study Drug (IMP) in a proper manner, so that quality and storage conditions are maintained during transport until arrival and receipt at pharmacy, safety is ensured and that all applicable regulations are met including The Guidelines of 5 November 2013 on <strong>Good Distribution Practice</strong> of medicinal products for human use (GDP) chapter 7 and 9.", "DISTRIBUTOR shall store, maintain and handle the Product in accordance with <strong>Good Distribution Practice</strong>, Applicable Laws, the UT Product package insert and UT\u2019s written instructions, including any requirements with respect to racking, temperature, light, darkness, vibration and rotation.", "The Supplier shall deliver the pharmaceutical drug that is produced, transported and stored in accordance with current GMP / GDP (Good Manufacturing Practice / <strong>Good Distribution Practice</strong>) The pharmaceutical drug shall be delivered to the Hospital Pharmacy Enterprise in accordance with Incoterms DDP.", "Especially concerning current EU <strong>Good Distribution Practice</strong> (hereinafter referred to as \u2018GDP\u2019) guidance (2013/C343/01), and as set out in Directive 2001/83/EC, as amended, for the purchase, storage and transportation of pharmaceutical products for parallel distribution within the European Economic Area."], "related": [["certification-practice-statement", "Certification Practice Statement", "Certification Practice Statement"], ["group-practice", "Group practice", "Group practice"], ["federal-trade-commission-act", "Federal Trade Commission Act", "Federal Trade Commission Act"], ["fradulent-practice", "fradulent practice", "fradulent practice"], ["equal-credit-opportunity-act", "Equal Credit Opportunity Act", "Equal Credit Opportunity Act"]], "related_snippets": [], "updated": "2026-05-07T05:32:46+00:00"}, "json": true, "cursor": ""}}